# Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.

> **NCT07411378** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Biophytis** · enrollment: 164 (estimated)

## Conditions studied

- Muscle Wasting
- Obesity & Overweight
- Obesity

## Interventions

- **DRUG:** BIO101
- **OTHER:** Placebo
- **DRUG:** Semaglutide

## Key facts

- **NCT ID:** NCT07411378
- **Lead sponsor:** Biophytis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2027-06
- **Final completion:** 2027-08
- **Target enrollment:** 164 (ESTIMATED)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07411378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07411378, "Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07411378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*